

DAFTAR PUSTAKA

1. Ganapati NPD. Profil Epidemiologi Penyakit Kanker Di Rumah Sakit Umum Pusat Nasional Cipto Mangunkusumo Tahun 2008-2010. Universitas Indonesia; 2017.
2. American Cancer Society. Cancer Facts & Figures 2019. American Cancer Society. 2019. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf> - Diakses Januari 2021
3. International Agency for Research on Cancer (IARC). Indonesia - Global Cancer Observatory. Vol. 858, Globocan. 2020.
4. Kementerian Kesehatan RI. Situasi Penyakit Kanker. Vol. 31, Pusat Data dan Informasi Kemenkes RI. Jakarta Selatan; 2018.
5. RSUP Dr. M. Djamil. 10 Besar Penyakit Rawat Jalan Tahun 2020. Laporan RSUP Dr. M. Djamil. 2020. <http://rsdjamil.co.id/laporan-rumah-sakit/> - Diakses Januari 2021
6. Rambe IR, Asri A, Adrial A. Profil Tumor Ganas Ovarium di Laboratorium Patologi Anatomi Fakultas Kedokteran Universitas Andalas Periode Januari 2011 Sampai Desember 2012. *J Kesehat Andalas*. 2014;3(1):54–7.
7. Pradjatmo H. Upaya Meningkatkan Kelangsungan Hidup (survival) Penderita Kanker Ovarium: masalah dan tantangan. Universitas Gadjah Mada; 2018.
8. Wu R, Baker SJ, Hu TC, Norman KM, Fearon ER, Cho KR. Type I to type II ovarian carcinoma progression: Mutant Trp53 or Pk3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. *Am J Pathol*. 2013;182(4):1391–9.
9. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. *Lancet*. 2019;393(10177):1240–53.
10. Da Silva AC, Jammal MP, Crispim PCA, Murta EFC, Nomelini RS. The Role of Stroma in Ovarian Cancer. *Immunol Invest*. 2020;49(4):406–24.
11. Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. 2012;1–8.
12. Berek JS, Kehoe ST, Kumar L, Friedlander M. FIGO Cancer Report 2018 :

- Cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynecol Obstet*. 2018;143:59–78.
13. Rahestyningtyas E. Respon Kemoterapi Lini Kedua Gemcitabine Carboplatin Pada Pasien Kanker. Universitas Airlangga; 2018.
 14. Gabra H. Epithelial Ovarian Cancer. In: Dewhurst's Textbook Obstetrics & Gynaecology. 7th ed. Wiley Online Library; 2008. p. 625–35.
 15. Van Zyl B, Tang D, Bowden NA. Biomarkers of platinum resistance in ovarian cancer: What can we use to improve treatment. *Endocr Relat Cancer*. 2018;25(5):R303–18.
 16. Harsono AB. Kanker Ovarium: "The Silent Killer." *Indones J Obstet Gynecol Sci*. 2020;3(1):1–6.
 17. Sahil MF. Penatalaksanaan Kanker Ovarium Pada Wanita Usia Muda dengan Mempertahankan Fungsi Reproduksi. Universitas Sumatera Utara; 2008.
 18. Trihandini I, Nurrika D. Analisis Ketahanan Hidup Penderita Kanker Ovarium Epithelial di RS Dharmais Jakarta. *J Kesehat Masy Nas*. 2010;5:139–44.
 19. Dhitayoni IA, Budiana ING. Profil Pasien Kanker Ovarium di Rumah Sakit Umum Pusat Sanglah Denpasar - Bali Periode Juli 2013 - Juni 2014. *E-Jurnal Med*. 2017;2(1):1–9.
 20. Rahmawati H, ER D, Pakasi RD. Kanker Ovarium Disgerminoma. *Indones J Clin Pathol Med Lab*. 2016;19(1):51.
 21. Braat DDM. Diagnosis and management of ovarian cancer. *Eur J Obstet Gynecol Reprod Biol*. 1997;72(2):217.
 22. Aarenstrup Karlsen M, Høgdall C, Nedergaard L, Philipsen Prahm K, Schou Karlsen NM, Weng Ekmann-Gade A, et al. HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer. *Apmis*. 2016;124(12):1038–45.
 23. RS Kanker Dharmais. Hubungan Ekspresi Protein Bcl-2 Jaringan dengan Disease Free Survival 2 Tahun Pasien Kanker Epitel Ovarium di Rumah Sakit Dr. Soetomo, Surabaya. *Indones J Cancer*. 2015;9(1):1–18.
 24. Wijaya R, Murti K, Hafy Z. Hubungan Kadar CA-125 Dengan Subtipe Epitel Tumor Ganas Ovarium Pada Penderita Yang Dirawat Di RSUP Dr.

- Mohammad Hoesin Palembang Tahun 2013-2016. 2017;11–7.
25. Chen VW, Ph D, Ruiz B, Ph D, Killeen JL, Cote TR. Pathology and Classification of Ovarian Tumors.
 26. Waruwu D, Lukito JS, Soekimin. Ekspresi P53 Mutan dengan Jenis Histopatologik dan Derajat Diferensiasi Karsinoma Ovarium. *Majalah Patologi*. 2016;25(2):19–23.
 27. Ovarian Cancer Research Alliance. Ovarian Cancer : Risk Factor. Ovarian Cancer Research Alliance. 2021. <https://ocrahope.org/patients/about-ovarian-cancer/risk-factors/> - Diakses Januari 2021
 28. American Cancer Society. Ovarian Cancer Causes, Risk Factors, and Prevention. 2021;1–16.
 29. Irawan W. Hubungan Antara Human Epydidimis 4 (HE4) dengan Kanker Ovarium Tipe Epitelial Resisten. Universitas Hasanuddin; 2018.
 30. Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: Pathogenesis and Current Recommendations for Prophylactic Surgery. *J Turkish-German Gynecol Assoc*. 2019;20(1):47–54.
 31. Sabaruddin H, Armanza F. Korelasi Tumor Marker Cancer Antigen (CA-125) terhadap Kadar Hemoglobin, Leukosit, dan Platelet Limfosit Ratio pada Pasien Kanker Ovarium di RSUD ULIN Banjarmasin. *J Ilm Kedokt Wijaya Kusuma*. 2018;7(1):93–106.
 32. Rasmussen CB, Kjaer SK, Albieri V, Bandera E V., Doherty JA, Høgdall E, et al. Pelvic inflammatory disease and the risk of ovarian cancer and borderline ovarian tumors: A pooled analysis of 13 case-control studies. *Am J Epidemiol*. 2017;185(1):8–20.
 33. Kurman RJ, Shih I. The Origin and Pathogenesis of Epithelial Ovarian Cancer : A Proposed Unifying Theory. 2010;34(3):433–43.
 34. Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, et al. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. *Arch Gynecol Obstet*. 2016;293(4):695–700.
 35. Made N, Suastari P. Pemeriksaan Radiologi untuk Deteksi Kanker Ovarium. 2018;45(4):298–302.

36. Desai A. Epithelial ovarian cancer: An overview. *World J Transl Med.* 2014;3(1):1.
37. Charter JS, Jr LSD. Ovarian Cancer Tests and Treatment. *Natl Institutes Heal.* 2011;36(4):30–5.
38. Damia G, Broggini M. Platinum Resistance in Ovarian Cancer : Role of DNA Repair. 2019;1–15.
39. Kelland LR. Preclinical Perspectives on Platinum Resistance. 2000;1–8.
40. Khalidah AR. Literature Review: Mekanisme Resistensi Kemoterapi Berbasis Platinum. *J Kesehat.* 2020;11(1):151.
41. Colombo N. Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. *Eur J Cancer Suppl.* 2014;12(2):7–12.
42. Kementerian Kesehatan RI. Kelompok Usia. Departemen Kesehatan RI. 2009. <https://www.depkes.go.id/> - Diakses Juli 2021
43. Lertkhachonsuk A, Buranawongtrakoon S, Lekskul N, Rermluk N, Charakorn C. Serum CA19-9 , CA-125 and CEA as tumor markers for mucinous ovarian tumors. 2020;46(11):2287–91.
44. Fakhriani M. Perbandingan respon kemoterapi platinum pada kanker ovarium epitelial tipe serosum dengan musinosum di RSUP DR. M. Djamil Padang. 2021;
45. Septaprima M. Hubungan skor risk malignancy index dengan subtype kanker epitel ovarium di RSUP DR. M. Djamil Padang. 2020;
46. Desember J, Loho MF, Wagey FW. Gambaran jenis kanker ovarium di RSUP Prof . Dr . R . D . Kandou Manado. 2016;4:2–6.
47. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world : epidemiology and risk factors. 2019;287–99.
48. Karst AM, Drapkin R, Detection E. Ovarian Cancer Pathogenesis : A Model in Evolution. 2010;2010.
49. Ariningtyas ND. Ca 125 dan pemakaian klinis dalam penatalaksanaan kanker. 2018;02(02):73–82.
50. Rauh-hain JA, Krivak TC, Carmen MG, Olawaiye AB. Ovarian Cancer Screening and Early Detection in the General Population. 2011;4(1):15–21.
51. Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival - a

review of the epidemiological literature. 2009;20:1–20.

52. Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Mangioni C, et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. *Eur J Cancer*. 2013;49(2):520–30.
53. Pisano C, Greggi S, Tambaro R, Losito S, Iodice F, Maio MDI, et al. Activity of Chemotherapy in Mucinous Epithelial Ovarian Cancer: A Retrospective Study. 2005;3506:3501–5.
54. Cooke SL, Brenton JD, Way R. Evolution of platinum resistance in high-grade serous ovarian cancer. *Lancet Oncol*. 2011;12(12):1169–74.

